YOOZOO logo.PNG
6 New Games Unveiled and AI Playmate Launched: YOOZOO GAMES 616 "Youth Day" to Continue Global Expansion
June 16, 2024 10:00 ET | YOOZOO
Shanghai, China, June 16, 2024 (GLOBE NEWSWIRE) -- On June 16th, 2024, YOOZOO GAMES would celebrate its 15th anniversary with the 8th annual "616 Youth Day" under the theme "The Wonder of...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sprout Social, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPT
June 16, 2024 08:40 ET | The Rosen Law Firm PA
NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sprout Social, Inc. (NASDAQ: SPT) between November 2, 2023...
Okay Coin logo.PNG
OkayCoin Launches Pooled Staking for Ethereum to Enhance Accessibility and Returns
June 16, 2024 08:00 ET | OkayCoin
Los Angeles, CA, June 16, 2024 (GLOBE NEWSWIRE) -- OkayCoin, a leading platform in cryptocurrency staking, has announced the introduction of pooled staking for Ethereum, enabling a broader range...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Malibu Boats, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– MBUU
June 16, 2024 07:47 ET | The Rosen Law Firm PA
NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Malibu Boats, Inc. (NASDAQ: MBUU) between November 4, 2022...
July 30, 2021 - ROSEN LOGO.jpg
RBLX INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Roblox Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – RBLX
June 16, 2024 07:35 ET | The Rosen Law Firm PA
NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Roblox...
July 30, 2021 - ROSEN LOGO.jpg
מידע למשקיעי RBLX: רוזן, יועץ למשקיעים גלובלי, מעודד את משקיעי Roblox Corporation לקבל ייעוץ לפני תאריך יעד חשוב בתביעה ייצוגית בניירות ערך – RBLX
June 16, 2024 07:35 ET | The Rosen Law Firm PA
ניו יורק, June 16, 2024 (GLOBE NEWSWIRE) -- מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מודיע על הגשת תביעה ייצוגית בשם רוכשי ניירות ערך של Roblox...
July 30, 2021 - ROSEN LOGO.jpg
רוזן, יועץ למשקיעים מהימן, מעודד את משקיעי Marinus Pharmaceuticals, Inc. לקבל ייעוץ לפני תאריך יעד חשוב בתביעה ייצוגית בניירות ערך שהוגשה לראשונה על ידי החברה - MRNS
June 16, 2024 07:28 ET | The Rosen Law Firm PA
ניו יורק, June 16, 2024 (GLOBE NEWSWIRE) -- מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מזכיר לרוכשים את ניירות הערך של Marinus Pharmaceuticals, Inc....
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS
June 16, 2024 07:28 ET | The Rosen Law Firm PA
NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between...
Regeneron Logo.jpg
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
June 16, 2024 06:10 ET | Regeneron Pharmaceuticals, Inc.
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously...
Nurix.png
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
June 16, 2024 05:30 ET | Nurix Therapeutics, Inc.
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...